Pfizer, Arcadium Lithium, Richemont
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
Pfizer ( PFE 3.18%) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...
On top of this, Pfizer also faces key patent expirations of certain older products, and earlier estimated this will result in ...
Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen in the chart ...
Lower interest rates make these stand-out dividend payers must-see investments for those who want passive income.
In conjunction with the Seagen acquisition, Pfizer shifted its oncology focus from chemically made small-molecule drugs to ...
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday. Shares of Pfizer Inc PFE rose during ...
Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback